RANI Rani Therapeutics Holdings Inc - Ordinary Shares Class A

$RANI Does Rani have short-term expansion plans? Yes, Rani Therapeutics has active and concrete expansion plans for the short and medium term. ​Production Automation: Following its inclusion in the ETP, Rani is specifically focusing on automating its vertically integrated manufacturing process to scale capsule production from clinical trial volumes to commercial-scale manufacturing. ​Capacity and Facility Expansion: Rani is expanding its manufacturing capacity to produce its own drugs and serve as a CDMO/manufacturing partner for major pharmaceutical companies looking to formulate their biologic drugs into the RaniPill. ​Pipeline Expansion (including Obesity): Rani is rapidly expanding its clinical programs, including the development of the RaniPill for obesity treatments (RT-114 GLP-1/GLP-2 dual agonist) and large molecules like antibodies.

$RANI Wat happens is the stock price fails to rise above one dollar? Rani Therapeutics is facing a tight timeline to regain Nasdaq compliance and avoid a potential delisting. ​If the stock price fails to organically rise above $1.00 through positive clinical news or investor confidence in time, the company has concrete options available: ​Requesting an extension: If the initial 180-day grace period expires without compliance, Rani can apply for a second 180-day extension, provided theymeet all other Nasdaq listing requirements and state their intention to cure the deficiency. ​Executing a reverse stock split: This serves as the fastest and most common emergency option. By consolidating shares (for example, combining 10 existing shares into 1 new share), the stock price immediately increases tenfold, placing Rani comfortably back above the $1.00 threshold. ​Let us hope management will reserve a reverse stock split as a last resort.... LET US RISE AND SHINE !!!!

$RANI Strong with the Force, Rani Therapeutics is. ​No dilution, there will be: Funded through late 2027 ($53M cash), they are. Need new shares, they do not. ​Big Pharma, speak with them they do: Active commercial talks with ~6 top pharma giants, there are. Impressed by stellar Phase 1a data (>150% bioavailability), they remain. ​Production, scale up it will: Automated line growing from 1,500 to 10,000 pills a day, it is. Ready for the future, Rani shall be!

$RANI is holding up surprisingly well in this biotech market that is being hurt badly by high US Treasury interest rates. Just imagine how the stock would do in a more positive market environment.

$RANI shorts desperate to cover at low levels but no one is selling. Not even 100k volume. Still 7.12 million shares to cover…easily $2- $3.

$RANI I’ve been flipping this penny stock for more than a year and believe me when I say, it always make me money. Just buy the dip 💚💚💚

$RANI oral pill technology has great potential 10- 20% of the world population suffers from a fear of needles ( trypanophobia) America’s youth is the largest needle phobic group

$RANI Great risk to reward with this company. Worse case scenario = delisting and 40 cents a share. We trigger a milestone payment from Chugai and we have the potential to run to $10 a share n the blink of an eye.

$RANI In any case, a reverse stock split requires a shareholder vote—and I haven't found anything on that yet; the vote must take place at least 20 days before the deadline, and the reverse split itself 10 days before the deadline... barring any requests for extensions, etc.

$RANI im tracking order book and i notice that even small tick worth 100 shares can move this stock 0,5% up/down. Float is tight, this will go to moon with proper catalist....

$RANI needs to pull a rabbit out of a hat pronto. Is the son of the Elon Musk of biotech a success or flop? We'll soon find out.

$RANI Drastically shorts DOWN… in August Shares Sold Short: ~6.39 million Short % of Float: 6.26% Short Ratio (Days to Cover): ~8.1 to 9.3 days

$RANI alongside the upcoming compliance deadline, Q3 window dressing may also have contributed to the slight decline seen recently. Curious to see how it evolves in the coming critical weeks.

$RANI ,.. 1,500/day is still being rolled out; 10,000/day is a future target. >150% bioavailability is exposure, not efficacy. “6 pharma giants” talking proves nothing, and Chugai milestones remain largely contingent. There are years of development between delivering a drug and “how do we sell it?” …

$RANI the good thing about this ticker besides it's tech and ongoing partnership discussions is it's prodominately retail owned.

$RANI No one is selling. Shorts need 8 million shares to cover. Some good news will trigger above $5 easily.

$RANI tell me why I should maintain faith with Supply chain risks, delisting risk, competition risk, complexity risks.

$RANI will Talat going to say tomorrow anything about extension cohort or something else to push price above 1$? Any ideas?

$RANI if Form 13G appears following completed and upcoming meetings then ill be adding